Top

Published in:

01-01-2009 | Letter to the Editor

Adult T-cell leukemia after immunosuppressive therapy for systemic lupus erythematosus

Authors: Yoshiko Shimamoto, Shosaku Nomura, Kazuyoshi Ishii, Michiomi Shimizu, Yoshio Ozaki, Tomoki Ito, Fumiaki Urase, Yasuhiro Maeda, Shirou Fukuhara

Published in: International Journal of Hematology | Issue 1/2009

Excerpt

Retroviruses, including human T-cell leukemia virus (HTLV)-1, are possible etiological factors for autoimmune diseases such as systemic lupus erythematosus (SLE) [1]. In particular, SLE patients can produce autoantibodies to the HTLV-1-related endogenous sequence (HRES)-1/p28 [2]. Adult T-cell leukemia (ATL) is a human malignancy associated with HTLV-1 and its diagnosis based on the clinicopathological findings and the presence of integrated HTLV-1 provirus in the DNA of tumor cells [3]. Here, we describe HTLV-1 carrier patient with SLE, who was presented with ATL after immunosuppressive therapy. …

Panem S, Ordonez NG, Kirstein WH, et al. C-type virus expression in systemic lupus erythematosus. N Engl J Med. 1976;295:470–5.CrossRefPubMed

Gergely P, Pullmann R, Stancato C, et al. Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus. Clin Immunol. 2005;116:124–34. doi:10.1016/j.clim.2005.04.002.CrossRefPubMed

Ohshima K, Kikuchi M, Masuda Y, et al. Human T-cell leukemia virus type I associated lymphadenitis. Cancer. 1992;69:239–48. doi:10.1002/1097-0142(19920101)69:1<239::AID-CNCR2820690139>3.0.CO;2-#.CrossRefPubMed

Lipka K, Tebbe B, Finckh U, et al. Absence of human T-lymphotrophic virus type I in patients with systemic lupus erythematosus. Clin Exp Dermatol. 1996;21:38–42. doi:10.1111/j.1365-2230.1996.tb00009.x.CrossRefPubMed

Akimoto M, Matsushita K, Suruga Y, et al. Clinical manifestations of human T lymphotropic virus type I-infected patients with systemic lupus erythematosus. J Rheumatol. 2007;34:1841–8.PubMed

Adelman MK, Marchalonis JJ. Endogenous retrovirus in systemic lupus erythematosus: candidate lupus viruses. Clin Immunol. 2002;102:107–16. doi:10.1006/clim.2001.5153.CrossRefPubMed

Suh WK, Cohen-Doyle MF, Fruh K, et al. Interaction of MHC class I molecules with the transporter associated with antigen processing. Science. 1994;264:1322–6. doi:10.1126/science.8191286.CrossRefPubMed

Alexandre C, Verrie B. Four regulatory elements in the human c-fos promoter mediate transactivation by HTLV-1 Tax protein. Oncogene. 1991;6:543–51.PubMed

Title: Adult T-cell leukemia after immunosuppressive therapy for systemic lupus erythematosus
Authors: Yoshiko Shimamoto
Shosaku Nomura
Kazuyoshi Ishii
Michiomi Shimizu
Yoshio Ozaki
Tomoki Ito
Fumiaki Urase
Yasuhiro Maeda
Shirou Fukuhara
Publication date: 01-01-2009
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 1/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-008-0239-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2009

A case of age-related EBV-associated B-cell lymphoproliferative disorder metachronously showing two distinct morphologic appearances, one of a polymorphic disease resembling classical Hodgkin lymphoma, and the other of a large-cell lymphoma

Identification of four novel mutations in F5 associated with congenital factor V deficiency

Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience

Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia

Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy

Successful treatment of myeloid neoplasms associated with PDGFRA rearrangement with imatinib mesylate

Keynote webinar | Spotlight on antibody–drug conjugates in cancer